## REMARKS

It is respectfully submitted that the amendments made to the claims herein are neither being presented nor made in response to the citation of any prior art known to the Applicant or the Applicant's attorneys. These claim amendments are further not made for any reason related to any statutory requirements for patentability. These claim amendments are made to more completely claim that to which the Applicant is entitled. Applicant's invention should only be considered limited by the claims as they now exist and the equivalents thereof. It is submitted that no new matter has been added. A marked-up copy of all pending claims after the amendments made herein is attached to this Preliminary Amendment as Exhibit B.

In view of the foregoing, Applicant respectfully requests the thorough and complete examination of this application and earnestly solicits an early notice of allowance.

Respectfully submitted,

JENKENS & GILCHRIST,
A Professional Corporation



Ross T. Robinson
Reg. No. 47,031

1445 Ross Avenue, Suite 3200
Dallas, Texas 75202-2799
(214) 965-7300
(214) 855-4300 (fax)

**Exhibit A**

METHOD [FOR]OF TREATMENT OF MALIGNANT NEOPLASMS AND [A] COMPLEX PREPARATION HAVING [ANTIMALIGNANT] ANTINEOPLASTIC ACTIVITY

**Exhibit B**

1. (AMENDED) A method of treatment of malignant neoplasms, the method comprising:

[injection of]injecting [alpha-fetoprotein (AFP), characterized in that AFP is injected as a component of the]a complex preparation comprising [additionally] alpha-fetoprotein (AFP), a [polyene antibiotic]cytotoxic substance, and a filler;

wherein a mass [in ]ratio of the AFP to the cytotoxic substance to the filler is (1-2):(60-100):(50-70) [1:(60-100):(50-70), and the preparation is injected parenterally in a course of 10 injections once in three days].

2. (AMENDED) A complex preparation[having antineoplastic activity,] comprising:

alpha-fetoprotein (AFP)[AFP,];

a cytotoxic substance; and

a filler[, characterized in that the preparation comprises a polyene antibiotic as a cytotoxic substance and polysaccharide or sugar as a filler];

wherein a mass ratio of the AFP to the cytotoxic substance to the filler is 1:(60-100:(50-70). [in the following quantitative ratio of the components, in mg: AFP 0.07-0.15 a polyene antibiotic 4.2-7.0 a filler 3.5-5.0]

3. (AMENDED) The [A]complex preparation of claim 2, [characterized in that the preparation]wherein the cytotoxic substance comprises a polyene antibiotic, the polyene antibiotic being selected from the group consisting of amphotericin B [or] and nystatin[ as a polyene antibiotic].

4. (AMENDED) [A] The complex preparation of claim 2, wherein the filler[characterized in that the preparation] comprises at least one of a polysaccharide and glucose, the polysaccharaide being selected from the group consisting of polyglykine, rheopolyglykine, and dextran[, or sugar, mainly glucose as a filler].

5. (NEW) The method of claim 1, wherein the cytoxic substance comprises a polyene antibiotic, the polyene antibiotic being selected from the group consisting of amphotericin B and nystatin.

6. (NEW) The complex preparation of claim 2, wherein the filler comprises at least one of a polysaccharide and glucose, the polysaccharaide being selected from the group consisting of polyglykine, rheopolyglykine, and dextran.

7. (NEW) The method of claim 1, further comprising injecting the complex preparation in a course of ten injections once in three days, wherein a single dose comprises 0.07-0.15 mg of the AFP, 4.2-7.0 mg of the cytotoxic substance, and 3.5-5.0 mg of the filler.

PATENT APPLICATION
DOCKET NO.: 53196-00002
0968/P/JO

____ Please charge my Deposit Account No. 10-0447 in the amount of $____ to cover the TOTAL FEE. This sheet is attached in duplicate.

CHARGE STATEMENT: If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136. The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and may be required under 37 CFR 1.16-1.18 (missing or insufficiencies only) now or hereafter relative to this application and for the resulting Official Document under 37 CFR 1.20, OR credit any overpayment to our Deposit Account No. 10-0447, for which purpose a duplicate copy of this sheet is attached.

**This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.**

Respectfully submitted,

JENKENS & GILCHRIST,
A Professional Corporation

By: 
Ross T. Robinson
Registration No.47,031

1445 Ross Avenue; Suite 3200
Dallas, Texas 75202-2799
Tel: 214/855-7300
Fax: 214/855-4300